---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-211760"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T03:44:21.662502+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Madrigal on track for MAESTRO-NASH topline data in Q4 2022; Q2 cash $211.8M

## Summary
- Topline data from Phase 3 MAESTRO-NASH biopsy study expected in Q4 2022; NDA filing planned for H1 2023.
- Cash, cash equivalents and marketable securities of $211.8M as of June 30, 2022, down from $270.3M at Dec 31, 2021.
- Q2 2022 operating expenses $70.3M (R&D $58.5M, G&A $11.8M) vs $61.7M in Q2 2021.
- Expanded market development activities; payer education sessions covering >80% of U.S. branded prescriptions.
- Plans to initiate MAESTRO-NASH Outcomes study in ~700 early NASH cirrhosis patients for full approval.

## SEC filing metadata
- accession: 0001193125-22-211760
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000119312522211760/0001193125-22-211760-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000119312522211760/d370174d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-211760
- JSON: https://secwatch.observer/filing/0001193125-22-211760.json
- Plain text: https://secwatch.observer/filing/0001193125-22-211760.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.